SCHEMBL660797

SCHEMBL660797

O=[N+]([O-])c1ccc(F)c(Br)c1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.48
ATM Q13315 1/20 0.48
MAPT P10636 6/20 0.47
ALDH1A1 P00352 4/20 0.47
HIF1A Q16665 2/20 0.47
VCAM1 P19320 1/20 0.44
CASP6 P55212 1/20 0.43
TSHR P16473 4/20 0.39
MAPK1 P28482 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
CYP3A4 P08684 2/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
CYP1A2 P05177 1/20 0.37
PKM P14618 1/20 0.37
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
VCP P55072 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29711979 1.00 TDP1 (0.48) TDP1ATMMAPTALDH1A1HIF1A
SCHEMBL6978734 0.85 TDP1 (0.50) TDP1ATMMAPTALDH1A1HIF1A
SCHEMBL632916 0.83 MAPT (0.56) TDP1ATMMAPTALDH1A1HIF1A
SCHEMBL29793298 0.83 MAPT (0.56) TDP1ATMMAPTALDH1A1HIF1A
SCHEMBL57498 0.80 TDP1 (0.54) TDP1ATMMAPTALDH1A1HIF1A
SCHEMBL29361654 0.80 TDP1 (0.54) TDP1ATMMAPTALDH1A1HIF1A
SCHEMBL33527983 0.80 TDP1 (0.50) TDP1ATMMAPTALDH1A1HIF1A
SCHEMBL10835047 0.80 GPR35 (0.50) TDP1ATMMAPTALDH1A1HIF1A
SCHEMBL22833410 0.80 CYP1A2 (0.52) TDP1ATMMAPTALDH1A1HIF1A
SCHEMBL3345953 0.80 ALDH1A1 (0.47) TDP1ATMMAPTALDH1A1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630529-B2 GCN2 modulator compounds Alesta Therapeutics BV (NL) 2026-05-19 US disclosed
US-20260125383-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2026-05-07 US disclosed
EP-4720037-A1 CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF 16380026 Canada Inc. (CA) 2026-04-08 EP disclosed
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2025-10-07 US disclosed
EP-4620470-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-24 EP disclosed
EP-4572755-A2 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-06-25 EP disclosed
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-06-05 US disclosed
WO-2025077767-A1 NOVEL I-TYPE TOPOISOMERASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊维康医药有限责任公司 2025-04-17 WO disclosed
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 US disclosed
WO-2024238406-A1 FUROPYRIDINE COMPOUNDS AS P53 MUTANT STABILIZER AND USES THEREOF FRONTIER MEDICINES CORPORATION (US) 2024-11-21 WO disclosed
WO-2002074773-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-09-26 WO disclosed
WO-2002074772-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-09-26 WO disclosed
US-5233091-A Cyclopropyl fluoroaniline as chemical intermediate for bactericides PFIZER INC. (US) 1993-08-03 US disclosed
US-5104868-A Bactericides PFIZER INC. (US) 1992-04-14 US disclosed
US-5103040-A Bactericides PFIZER INC. (US) 1992-04-07 US disclosed
US-5039682-A Bactericides PFIZER INC. (US) 1991-08-13 US disclosed
EP-0348088-A1 6-Fluoro-1,4-dihydroquinol-4-one-3-carboxylic acid derivatives and intermediates therefor PFIZER INC. (US) 1989-12-27 EP disclosed
EP-0184384-B1 SUBSTITUTED DIHYDROQUINOLONE CARBOXYLIC ACIDS, ANTI-BACTERIAL COMPOSITIONS CONTAINING THEM PFIZER INC. (US) 1989-08-02 EP disclosed
US-4623650-A BACTERICIDES PFIZER INC. (US) 1986-11-18 US disclosed
EP-0184384-A1 Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them PFIZER INC. (US) 1986-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630529-B2 GCN2 modulator compounds NR3C1, GCN1, EIF2AK4 TDP1 3878/4885ATM 4443/4885MAPT 4614/4885
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS TDP1 3784/4885ATM 2658/4885MAPT 229/4885
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 INMT, CARM1, KDM1B TDP1 940/4885ATM 2630/4885MAPT 3740/4885
US-20260125383-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF CGAS, PRKG1, GMPS TDP1 41/4885ATM 703/4885MAPT 4783/4885
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 TDP1 3132/4885ATM 1642/4885MAPT 2971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.